Revista De Investigacion Clinica-Clinical and Translational Investigation最新文献

{"title":"Epistasis Between Two Gene Variants of Leptin and Vascular Endothelial Growth Factor Genes in the Development of Primary Knee Osteoarthritis.","authors":"Matvey Sosa-Arellano,&nbsp;Norma C González-Huerta,&nbsp;Eugenio Morales-Hernández,&nbsp;Carolina Duarte-Salazar,&nbsp;Antonio Miranda-Duarte","doi":"10.24875/RIC.21000493","DOIUrl":"https://doi.org/10.24875/RIC.21000493","url":null,"abstract":"<p><strong>Background: </strong>The association of leptin (<i>LEP</i>) and vascular endothelial growth factor A (<i>VEGFA</i>) genes with the susceptibility to knee osteoarthritis (OA) has been analyzed; however, the epistasis between them has not been investigated.</p><p><strong>Objective: </strong>The objective of the study was to analyze the association of <i>LEP</i> and <i>VEGFA</i> variants and their interaction with primary knee OA in a Mexican Mestizo population.</p><p><strong>Methods: </strong>A case-control study was developed. Cases were ≥40 years, BMI ≤27 kg/m², with primary knee OA and radiologic Grade ≥2. Controls were participants with no knee OA and a radiologic Grade < 2. The rs2167270 of <i>LEP</i> and rs2010963 of <i>VEGFA</i> were genotyped. Genotypic association was tested under codominant, dominant, and recessive models. Uni- and multi-variate analyses were developed through non-conditional logistic regression. The multifactor dimensionality reduction algorithm was developed to detect epistasis.</p><p><strong>Results: </strong>Participants comprised 103 cases and 179 controls. Allelic and genotypic distributions did not show differences between the groups. Notwithstanding, a statistically significant interaction was observed between the <i>LEP</i> and <i>VEGFA</i> genes (p = 0.02) with a testing accuracy of 0.5199 and cross-validation consistency of 10/10. This interaction model confers an increased risk to knee OA (OR [95% CI] = 1.8 [1.1-2.9]).</p><p><strong>Conclusion: </strong>Interaction between <i>LEP</i> and <i>VEGFA</i> is related with genetic susceptibility to developing primary knee OA.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 2","pages":"081-089"},"PeriodicalIF":1.4,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39785153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Result Turnaround Time of RT-PCR for SARS-CoV-2 is the Main Cause of COVID-19 Diagnostic Delay: A Country-Wide Observational Study of Mexico and Colombia.","authors":"Isaac Núñez,&nbsp;Pablo F Belaunzarán-Zamudio,&nbsp;Yanink Caro-Vega","doi":"10.24875/RIC.21000542","DOIUrl":"https://doi.org/10.24875/RIC.21000542","url":null,"abstract":"<p><strong>Background: </strong>Delay in COVID-19 diagnosis due to late real-time reverse transcription-polymerase chain reaction reporting has been described to be an important cause of suboptimal COVID-19 surveillance and outbreak containment.</p><p><strong>Objective: </strong>The objective of the study was to determine the duration of diagnostic delay due to test turnaround time and its association with marginalization status.</p><p><strong>Methods: </strong>In this observational study using national open data of Mexico and Colombia, we quantified the delay in COVID-19 diagnosis that occurred in both countries. We considered two periods that contributed to the delay in diagnosis: the time from symptom onset until testing <i>(delay-one)</i> and test turnaround time <i>(delay-two)</i>. Marginalization status was determined according to country-specific scores.</p><p><strong>Results: </strong>Among 3,696,773 patients from Mexico and Colombia, <i>delay-two</i> was generally longer than <i>delay-one</i>. Median <i>delay-one</i> was 3 days and delay-two 7 days in Colombia, while in Mexico, they were 3 days and 4 days, respectively. In Colombia, worse marginalization status prolonged <i>delaytwo</i>. In Mexico, a lower number and percentage of rapid tests were performed in areas with worse marginalization.</p><p><strong>Conclusion: </strong>Diagnostic delay was mostly due to test turnaround time. Marginalization status was an important barrier to diagnostic test access.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 2","pages":"071-080"},"PeriodicalIF":1.4,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39941009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated with Development of Acute Kidney Injury After Liver Transplantation.","authors":"Rodrigo Catalán,&nbsp;José V Jiménez-Ceja,&nbsp;Rodolfo Rincón-Pedrero,&nbsp;Antonio Olivas-Martínez,&nbsp;Armando J Martínez-Rueda,&nbsp;Silvana Bazúa-Valenti,&nbsp;Diego L Carrillo-Pérez,&nbsp;Leoneli I Grajeda-Medina,&nbsp;Ignacio García-Juárez,&nbsp;Mario Vilatobá,&nbsp;Juan A Ortega-Trejo,&nbsp;Rosalba Pérez-Villalva,&nbsp;Norma A Bobadilla,&nbsp;Erika Moreno,&nbsp;Gerardo Gamba","doi":"10.24875/RIC.21000496","DOIUrl":"https://doi.org/10.24875/RIC.21000496","url":null,"abstract":"<p><strong>Background: </strong>Early post-liver transplant (LT) acute kidney injury (AKI) has been associated with worse short-term and long-term outcomes, but the incidence and risk factors in our population are unknown.</p><p><strong>Methods: </strong>We designed a prospective, singlecenter, longitudinal cohort study to determine the incidence of AKI during the immediate postoperative period of LT, and to identify the risk factors associated with AKI after LT. Pre-operative and intraoperative variables were analyzed to determine if there was any correlation with the development of post-operative AKI.</p><p><strong>Results: </strong>Eighty-six patients were included in the final analysis; from them, 45 (52%) developed AKI in the following 30 days after LT. The presence of hepatic encephalopathy prior to LT was the factor most strongly associated with the development of AKI (Relative Risk 3.67, 95% Confidence Interval 1.08-8.95). Other factors associated with AKI development were male gender and a higher serum lactate during surgery.</p><p><strong>Conclusion: </strong>AKI was a frequent complication that significantly worsened the prognosis of LT recipients and was associated with an increased 30-day mortality rate. The presence of hepatic encephalopathy strongly predicted the development of severe AKI.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 2","pages":"090-096"},"PeriodicalIF":1.4,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39941012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis.","authors":"Yulino Castillo-Núñez,&nbsp;Enrique Morales-Villegas,&nbsp;Carlos A Aguilar-Salinas","doi":"10.24875/RIC.21000416","DOIUrl":"https://doi.org/10.24875/RIC.21000416","url":null,"abstract":"<p><p>The term \"triglyceride-rich lipoproteins\" (TRLs) includes chylomicrons and their remnants, very low-density lipoproteins (VLDL), and intermediate-density lipoproteins (IDL). In this manuscript, the mechanisms by which atherogenic TRLs contribute to the formation of atheroma plaques are reviewed. Cholesterol from TRLs that can be retained in the subendothelial space (i.e., remnants, DLs, and small VLDLs) contributes to the genesis of atherosclerosis. Triglycerides of atherogenic TRLs induce inflammation of the arterial wall. Mechanisms that explain the involvement of TRLs in atherosclerosis are the generation of pro-atherogenic changes in high-density lipoproteins and low-density lipoproteins, accumulation of TRLs in plasma, and their passage to the subendothelial space where they cause endothelial dysfunction and inflammation of the vascular wall. Furthermore, plasma accumulation of TRLs causes hyperviscosity and a procoagulant state. Finally, this manuscript summarizes the controversial aspects of the clinical approach and the treatment of cases with dyslipidemia explained by atherogenic TRLs.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 2","pages":"061-070"},"PeriodicalIF":1.4,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39609127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Admission Monocyte/HDL Ratio Predicts Adverse Cardiac Remodeling After St-Elevation Myocardial Infarction.","authors":"Ferhat Eyyupkoca,&nbsp;Onur Yildirim,&nbsp;Serkan Sivri,&nbsp;Mehmet Ali-Felekoglu,&nbsp;Bekir Demirtas,&nbsp;Mehmet Sait-Altintas,&nbsp;Burcu Ugurlu-Ilgin,&nbsp;Omer Faruk-Ates","doi":"10.24875/RIC.21000599","DOIUrl":"https://doi.org/10.24875/RIC.21000599","url":null,"abstract":"<p><strong>Background: </strong>Inflammation plays a critical role in cardiac remodeling after myocardial infarction (MI). Monocyte to high-density lipoprotein-cholesterol (HDL-C) ratio (MHR) has emerged as a potential indicator of inflammation.</p><p><strong>Objectives: </strong>The study aimed to investigate the prognostic role of MHR at the time of hospital admission in late cardiac remodeling and subsequent 1-year mortality in an academic training and research hospital.</p><p><strong>Methods: </strong>This prospective multicenter study included 231 patients with acute ST-elevation MI. Left ventricular (LV) functions and volumes were assessed by cardiac magnetic resonance (CMR) imaging at 2 weeks and 6 months post-MI. The definition of adverse cardiac remodeling (AR) was based on the increase of LV end-diastolic volume by ≥ 12% at 6 months post-MI. All patients were followed for survival for 1 year after the second CMR imaging measurements.</p><p><strong>Results: </strong>At 6 months post-MI, 20 patients (23.8%) exhibited AR. The median MHR was higher in the AR group compared to the group without AR (2.2 vs. 1.5, p < 0.001). A positive correlation was found between MHR and infarct size in the groups with and without AR. High MHR was an independent predictor of AR (OR: 3.21, p = 0.002). The cut-off value of MHR in predicting AR was found to be >1.6 with 92.7% sensitivity and 70.1% specificity (AUC ± SE: 0.839 ± 0.03, p < 0.001). Mortality risk was 5.62-fold higher in the group with MHR of >1.6 (HR: 5.62, p < 0.001).</p><p><strong>Conclusions: </strong>These results indicate that admission MHR is a useful tool to predict patients with AR who are at risk of progression to heart failure and mortality after MI.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 2","pages":"104-112"},"PeriodicalIF":1.4,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39779040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Value of C-Reactive Protein/Albumin Ratio in Acute Pulmonary Embolism.","authors":"Sevgi Özcan,&nbsp;Esra Dönmez,&nbsp;Sevil Yavuz Tuğrul,&nbsp;İrfan Şahin,&nbsp;Orhan İnce,&nbsp;Murat Ziyrek,&nbsp;Sinan Varol,&nbsp;Serkan Karahan,&nbsp;Ertuğrul Okuyan","doi":"10.24875/RIC.21000547","DOIUrl":"https://doi.org/10.24875/RIC.21000547","url":null,"abstract":"<p><strong>Background: </strong>Serum C-reactive protein (CRP) to albumin ratio (CAR) has been defined as an inflammation-based prognostic marker. We evaluated the association and prognostic value of CRP/albumin ratio in patients with pulmonary embolism (PE).</p><p><strong>Methods: </strong>A total of 256 patients with acute PE who were hospitalized between March 2016 and December 2020 were retrospectively reviewed. PE severity index (PESI) was calculated. Serum levels of CRP and albumin that were obtained at the time of admission were used for calculation. CAR was evaluated for correlation with PESI, and thus, foresee the risk of death due to PE.</p><p><strong>Results: </strong>There were 186 patients eligible for inclusion. 54 patients were in intermediate, 34 patients were in high risk and 98 patients were in very high-risk group according to PESI score. In the correlation analysis, we observed moderate positive correlations between CRP/albumin ratio, troponin and PESI score (r = 0.584, p < 0.0001; r = 521, p < 0.0001, respectively). Regression analysis revealed that only CRP/albumin ratio and PESI score were independent risk factors associated with 6-month mortality of acute PE patients. The AUC for CRP/albumin ratio was 0.643, 0.751, and 0.763 for 30-day, 90-day, and 6-month mortality, respectively (95% CI: 0.550-0.737, 0.672-0.830, 0.687-0.838]. A cut-off value of 5.33 for CRP/albumin ratio was associated with 65.3% sensitivity and 65.6% specificity in predicting 6-month mortality.</p><p><strong>Conclusion: </strong>The CRP/albumin ratio, an inexpensive and easily measurable laboratory variable, may be a useful prognostic marker of PE, especially when other causes that alter serum levels are excluded from the study.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 2","pages":"097-103"},"PeriodicalIF":1.4,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39881053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Revisit Related to Discharge the Sixty-one Spanish Emergency Department Medical Centers Without Hospitalization in Patients with COVID-19 Pneumonia. A Prospective Cohort Study UMC-Pneumonia COVID-19.","authors":"J. Jacob, Arantxa Albert-Casado, Juan G Del-Castillo, P. Llorens-Soriano, Sonia Jiménez-Hernández, G. Burillo-Putze, A. Martín-Martínez, F. Martín-Sánchez, E. J. García-Lamberechts, P. Piñera-Salmerón, A. Alquézar-Arbé, Carles Ferre-Losa, María Á Juan-Gómez, Leticia Serrano-Lázaro, José Noceda-Bermejo, M. Salido-Mota, María J Fortuny-Bayarri, M. González-Tejera, José M Ferreras-Amez, Elena Díaz-Fernández, Eva Quero-Motto, Ana Peiró-Gómez, Enrique Martín-Mojarro, F. Llopis-Roca, Arturo Huerta-García, Jorge Pedraza-García, Napoleón Meléndez-Cálix, José V Brazó-Aznar, M. J. Cano-Cano, Ò. Miró","doi":"10.24875/RIC.22000021","DOIUrl":"https://doi.org/10.24875/RIC.22000021","url":null,"abstract":"Background\u0000Information is needed on the safety and efficacy of direct discharge from the emergency department (ED) of patients with COVID-19 pneumonia.\u0000\u0000\u0000Objectives\u0000The objectives of the study were to study the variables associated with discharge from the ED in patients presenting with COVID-19 pneumonia, and study ED revisits related to COVID-19 at 30 days (EDR30d).\u0000\u0000\u0000Methods\u0000Multicenter study of the SIESTA cohort including 1198 randomly selected COVID patients in 61 EDs of Spanish medical centers from March 1, 2020, to April 30, 2020. We collected baseline and related characteristics of the acute episode and calculated the adjusted odds ratios (aOR) for ED discharge. In addition, we analyzed the variables related to EDR30d in discharged patients.\u0000\u0000\u0000Results\u0000We analyzed 859 patients presenting with COVID-19 pneumonia, 84 (9.8%) of whom weredischarged from the ED. The variables independently associated with discharge were being a woman (aOR 1.890; 95%CI 1.176 3.037), age < 60 years (aOR 2.324; 95%CI 1.353-3.990), and lymphocyte count > 1200/mm3 (aOR 4.667; 95%CI 1.045-20.839). The EDR30d of the ED discharged group was 40.0%, being lower in women (aOR 0.368; 95%CI 0.142-0.953). A totalof 130 hospitalized patients died (16.8%) as did two in the group discharged from the ED (2.4%) (OR 0.121; 95%CI 0.029-0.498).\u0000\u0000\u0000Conclusion\u0000Discharge from the ED in patients with COVID-19 pneumonia was infrequent and was associated with few variables of the episode. The EDR30d was high, albeit with a low mortality.","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"44 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2022-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88049650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Antihypertensive medication].","authors":"R. Navarrete","doi":"10.1002/9781119799412.ch5","DOIUrl":"https://doi.org/10.1002/9781119799412.ch5","url":null,"abstract":"","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"37 1","pages":"317-27"},"PeriodicalIF":1.4,"publicationDate":"2022-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75543625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splitting the Total Dose of Cyclophosphamide in Two Blocks Apart during the Conditioning of Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Results in Diminished Cardiotoxicity: Experience in 1,000 Patients.","authors":"Juan Carlos Olivares-Gazca,&nbsp;Francisco Guerrero-Pesqueira,&nbsp;Iván Murrieta-Alvarez,&nbsp;Yahveth Cantero-Fortiz,&nbsp;Andrés A León-Peña,&nbsp;José M Priesca-Marín,&nbsp;David Gomez-Almaguer,&nbsp;Andrés Gomez-De-Leon,&nbsp;Guillermo J Ruiz-Delgado,&nbsp;Guillermo J Ruiz-Argüelles","doi":"10.24875/RIC.21000206","DOIUrl":"https://doi.org/10.24875/RIC.21000206","url":null,"abstract":"Autologous hematopoietic stem cell transplantation (HSCT) has been given to persons with multiple sclerosis (MS) for over 20 years, and more than 3000 HSCTs have been done worldwide1,2. Transplant-related mortality in MS managed with HSCT, was considered a limiting factor but has decreased to < 2%2.","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 1","pages":"1-3"},"PeriodicalIF":1.4,"publicationDate":"2022-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39394954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center.","authors":"Bernardo A Martínez-Guerra,&nbsp;Nereyda A de-León-Cividanes,&nbsp;Karla M Tamez-Torres,&nbsp;Carla M Román-Montes,&nbsp;Sandra Rajme-López,&nbsp;Edgar Ortiz-Brizuela,&nbsp;Carlos A Aguilar-Salinas,&nbsp;Juan Sierra-Madero,&nbsp;José Sifuentes-Osornio,&nbsp;Alfredo Ponce-de-León,&nbsp;María F González-Lara","doi":"10.24875/RIC.21000404","DOIUrl":"https://doi.org/10.24875/RIC.21000404","url":null,"abstract":"<p><strong>Background: </strong>Trials evaluating safety and efficacy of tocilizumab in coronavirus disease 19 (COVID-19) show contradictory results.</p><p><strong>Objective: </strong>The objective of the study was to evaluate the effect of tocilizumab in hospital mortality among patients with severe COVID-19 in a third-level medical center.</p><p><strong>Methods: </strong>This prospective cohort study included patients with severe and critical COVID-19. Primary outcome was death during hospitalization. Secondary outcomes included invasive mechanical ventilation (IMV), days on IMV, ventilator-free days (VFDs), length of hospital stay (LOS), and development of hospitalacquired infections (HAIs). Bivariate, multivariate, and propensity score matching analysis were performed.</p><p><strong>Results: </strong>During the study period, 99/794 (12%) patients received tocilizumab. Male patients, health care workers, and patients with increased inflammatory markers received tocilizumab more frequently. No difference in hospital mortality was observed between groups (34% vs. 34%, p = 0.98). Tocilizumab was not independently associated with mortality. No significant treatment effects were observed in propensity score analysis. IMV was more frequent (46% vs. 11%, p < 0.01) and LOS was longer (12 vs. 7 days, p < 0.01) in the tocilizumab group, reflecting increased severity. Although HAIs were more frequent in the tocilizumab group (22% vs. 10%, p < 0.01), no difference was seen after adjusting for IMV (38% vs. 40%, p = 0.86).</p><p><strong>Conclusions: </strong>In our study, tocilizumab was not associated with decreased hospital mortality among patients with severe COVID-19.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"74 1","pages":"40-50"},"PeriodicalIF":1.4,"publicationDate":"2022-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39517946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}